Investigating how certain microRNAs are degraded in T-cell leukemia
Official title: Exploring microRNA degradation in T-cell acute lymphoblastic leukemia
Funded at University of Florida · NIH-10886091 · Data updated 2026-11-12
This study is looking at how tiny molecules called microRNAs affect T-cell acute lymphoblastic leukemia (T-ALL) and aims to find new ways to make chemotherapy work better for patients by understanding how a specific mRNA interacts with these microRNAs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $478,652 |
| NIH project number | 5R01CA282812-02 |
| Project ID | NIH-10886091 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with T-cell acute lymphoblastic leukemia who are undergoing or considering chemotherapy.
✕Less likely to help
Patients with other types of leukemia or those not currently receiving treatment for T-ALL may not benefit from this research.
What this research studies
This research focuses on understanding the role of microRNAs in T-cell acute lymphoblastic leukemia (T-ALL), a type of cancer affecting the blood and bone marrow. The team will explore how a specific mRNA, BIM, can degrade two microRNAs that are typically involved in cancer progression. By examining this unique interaction, the researchers aim to uncover new strategies for enhancing the effectiveness of chemotherapy treatments. Additionally, they will develop methods to identify other mRNAs that may influence microRNA levels in T-ALL patients.
Why it matters
Potential benefit: If successful, this research could lead to improved chemotherapy outcomes for patients with T-cell acute lymphoblastic leukemia.
How similar studies have gone: While the specific approach of mRNA-induced microRNA degradation is novel, similar research has shown promise in understanding gene regulation in cancer.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Xie, Mingyi — University of Florida
- Study coordinator: Xie, Mingyi
Related research
Other NIH-funded projects on the same topics.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
-
Genomics of childhood ALL across diverse populations
A large international study will look at why children everywhere get acute lymphoblastic leukemia and how genetics may influence risk.
-
Combinatorial targeting for high-risk B-cell ALL treatment
A research effort at West Virginia University is exploring a combination therapy for adult B-cell acute lymphoblastic leukemia using targeted gene silencing and a small-molecule compound to improve treatment in patients.
-
Understanding why Latino children have a higher risk of childhood ALL
This project looks at why Latino children are more likely to develop acute lymphoblastic leukemia and whether genetic ancestry plays a role, with the goal of improving prevention and outcomes.
-
Targeting obesity to improve survival for children with ALL
A new approach explores whether reducing obesity-related factors can make chemotherapy work better for kids with acute lymphoblastic leukemia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.